<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474903</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00838</org_study_id>
    <secondary_id>NCI-2009-00838</secondary_id>
    <secondary_id>MAY04-4-01</secondary_id>
    <secondary_id>CDR0000544180</secondary_id>
    <secondary_id>MAYO-MAY04-4-01</secondary_id>
    <secondary_id>MAY04-4-01</secondary_id>
    <secondary_id>N01CN35000</secondary_id>
    <nct_id>NCT00474903</nct_id>
  </id_info>
  <brief_title>Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus</brief_title>
  <official_title>Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying the effect of esomeprazole magnesium and aspirin
      on tissue PGE2 levels compared with esomeprazole and placebo. This type of chemoprevention
      treatment investigates the use of certain drugs to assess whether they assist in the
      prevention of cancer. The use of esomeprazole magnesium with or without aspirin may help
      prevent esophageal cancer in patients with Barrett esophagus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the effects of a 28 day intervention with aspirin 81 mg placebo orally (PO) once
      daily (QD) + aspirin 325 mg placebo PO QD + esomeprazole 40 mg PO BID versus aspirin 81 mg PO
      QD + aspirin 325 mg placebo PO QD + esomeprazole 40 mg PO BID versus aspirin 325 mg PO QD +
      aspirin 81 mg placebo PO QD + esomeprazole 40 mg PO BID on the absolute change in tissue
      prostaglandin E2 (PGE2) concentration, as determined from Barrett's esophagus mucosal biopsy
      samples obtained pre- and post-intervention (i.e. two pair-wise comparisons of two different
      doses of active aspirin regimens versus aspirin placebo group), Specifically, the two active
      aspirin + esomeprazole arms will be independently analyzed to see if they significantly
      reduce the mean tissue PGE2 concentration from Pre- to Post-intervention as compared to the
      aspirin placebo + esomeprazole arm.

      SECONDARY OBJECTIVES:

      I. To determine if the change in the tissue PGE2 concentration decreases significantly in the
      aspirin placebo + esomeprazole arm.

      II. To compare the change in mean tissue PGE2 concentration between the two active
      intervention arms to determine which one appears the most promising for further testing.

      III. To assess the effects of the three agents (arms) with respect to proliferation (Ki-67),
      apoptosis (caspase-3 expression), COX-2 expression, and p16 methylation using Pre- and
      Post-Intervention biopsy samples obtained from Barrett's mucosal tissue.

      IV. To evaluate all adverse events associated with each of the three intervention arms.

      V. To provide exploratory summaries of PGE2 concentration values by patient subgroups of
      interest.

      VI. To provide descriptive summaries of the esophagogastroduodenoscopy (EGD) results, the
      rate of dysplasia, adverse events, and the Run-In Agent compliance on all participants that
      signed a consent form and started the Run-In phase of the trial.

      VII. To establish a biospecimen repository archive for future correlative studies.

      OUTLINE: This is a multicenter, randomized, double-blind, placebo-controlled study. Patients
      are stratified according to dysplasia status, gender, and length of Barrett segment of
      circumferential involvement (5 cm vs = 5 cm). Patients are randomized to 1 of 3 treatment
      arms.

      ARM I: Patients receive two oral placebos once daily and oral esomeprazole magnesium twice
      daily.

      ARM II: Patients receive oral acetylsalicylic acid (aspirin) and oral placebo once daily and
      oral esomeprazole magnesium twice daily.

      ARM III: Patients receive a higher-dose of oral aspirin (higher than in arm II) and a
      lower-dose of oral placebo (lower than in arm II) once daily and oral esomeprazole magnesium
      twice daily.

      In all arms, treatment continues for 28 days in the absence of unacceptable toxicity. Tissue
      samples are collected before and after treatment and examined for tissue-based biomarkers
      (i.e., PGE_2, Ki-67, caspase-3 apoptosis, and cyclooxygenase-2) by immunohistochemistry,
      enzyme immunoassay, Western blot, and polymerase chain reaction.

      After completion of study therapy, patients are followed 7 - 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples</measure>
    <time_frame>Baseline to 30 days after completion of study treatment</time_frame>
    <description>The mean tissue PGE2 is reported for each Arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to the interventional agent, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The number of patients reporting adverse events will be tabulated by grade.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (placebo, esomeprazole magnesium)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (low-dose aspirin, esomeprazole magnesium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (higher-dose aspirin, esomeprazole magnesium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (low-dose aspirin, esomeprazole magnesium)</arm_group_label>
    <arm_group_label>Arm III (higher-dose aspirin, esomeprazole magnesium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole magnesium</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (placebo, esomeprazole magnesium)</arm_group_label>
    <arm_group_label>Arm II (low-dose aspirin, esomeprazole magnesium)</arm_group_label>
    <arm_group_label>Arm III (higher-dose aspirin, esomeprazole magnesium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (placebo, esomeprazole magnesium)</arm_group_label>
    <arm_group_label>Arm II (low-dose aspirin, esomeprazole magnesium)</arm_group_label>
    <arm_group_label>Arm III (higher-dose aspirin, esomeprazole magnesium)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Barrett esophagus, meeting all of the following criteria:

               -  Presence of specialized columnar epithelium anywhere in the tubular esophagus
                  with ≥ 2 cm of circumferential involvement

               -  No evidence of high-grade dysplasia or cancer by esophagogastroduodenoscopy (EGD)

               -  No prior histologically confirmed esophageal dysplasia, including cancer

          -  Adequate Barrett mucosa, defined as ≥ 4 of 8 research samples with≥ 50% intestinal
             metaplasia in research biopsies

          -  No ulcer, erosion, plaque, nodule, stricture, or other luminal irregularity within the
             Barrett's segment or erosive esophagitis (Los Angeles classification &gt; grade A)
             detected at pre-intervention EGD exam

          -  Eastern Cooperative Group (ECOG) performance status 0-2

          -  Hemoglobin normal

          -  Platelet count ≥ 100,000/mm³

          -  Aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Bilirubin ≤ 2.5 times ULN

          -  Creatinine ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No nasal polyps associated with asthma or induced or exacerbated by aspirin

          -  No malignancy within the past 5 years except for nonmelanoma skin cancer

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to the study agents or rescue medication

          -  No history of endoscopically or radiographically diagnosed peptic ulcer disease
             (bleeding or nonbleeding)

          -  No other uncontrolled illness including, but not limited to, any of the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Bleeding disorder

               -  Vitamin K deficiency

               -  Alcohol abuse (defined as ingestion of ≥ 3 drinks per day)

               -  Psychiatric illness or social situations that would limit study compliance

          -  At least 3 months since prior chronic use (defined as ≥ 7 days during the 3 months
             preceding the beginning of the Run-in phase) of acetylsalicylic acid (aspirin),
             nonsteroidal antiinflammatory drug (NSAIDs), or selective cyclooxygenase (COX-2)
             inhibitors

          -  At least 3 months since prior investigational agents except innocuous agents with no
             known interaction with the study agents (e.g., standard dose multivitamins or topical
             agents for limited skin conditions)

          -  No prior fundoplication, bariatric surgery, or any other major upper gastrointestinal
             surgery

               -  Prior cholecystectomy allowed

          -  No other concurrent NSAIDs (including aspirin) or selective COX-2 inhibitor therapy

          -  No concurrent anticoagulant drugs including, but not limited to, any of the following:

               -  Warfarin

               -  Heparin

               -  Low-molecular weight heparin

               -  Clopidogrel bisulfate

               -  Extended-release dipyridamole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Limburg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>January 8, 2014</results_first_submitted>
  <results_first_submitted_qc>June 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>June 2, 2014</last_update_submitted>
  <last_update_submitted_qc>June 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 122 patients were randomized. Two patients withdrew due to an inadequate number of biopsies and a finding of high-grade dysplasia. Six participants were not evaluable for the primary endpoint due to sample-related issues (e.g., improper temperature, lost or delayed samples), leaving 114 evaluable participants for the primary endpoint.</recruitment_details>
      <pre_assignment_details>Of the 120 participants in the intervention cohort, 114 were evaluable for the primary endpoint (n = 29, 42, and 43 in Arm I, Arm II, and Arm III, respectively).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Placebo, Esomeprazole Magnesium)</title>
          <description>Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium)</title>
          <description>Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
        <group group_id="P3">
          <title>Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium)</title>
          <description>Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two patients from ARM II withdrew due to an inadequate number of biopsies and were not included in baseline measures.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Placebo, Esomeprazole Magnesium)</title>
          <description>Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium)</title>
          <description>Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium)</title>
          <description>Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="32" upper_limit="86"/>
                    <measurement group_id="B2" value="59" lower_limit="34" upper_limit="81"/>
                    <measurement group_id="B3" value="59" lower_limit="35" upper_limit="82"/>
                    <measurement group_id="B4" value="60" lower_limit="32" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples</title>
        <description>The mean tissue PGE2 is reported for each Arm.</description>
        <time_frame>Baseline to 30 days after completion of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo, Esomeprazole Magnesium)</title>
            <description>Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
esomeprazole magnesium: Given orally placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium)</title>
            <description>Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium)</title>
            <description>Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples</title>
          <description>The mean tissue PGE2 is reported for each Arm.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.6" spread="229.68" lower_limit="-745.2" upper_limit="454.7"/>
                    <measurement group_id="O2" value="-123.9" spread="284" lower_limit="-976.6" upper_limit="789"/>
                    <measurement group_id="O3" value="-174.9" spread="263.62" lower_limit="-1113.6" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0955</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0204</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to the interventional agent, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The number of patients reporting adverse events will be tabulated by grade.</description>
        <time_frame>Up to 30 days after completion of study treatment</time_frame>
        <population>All 120 patients that took study medication were evaluable for this secondary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo, Esomeprazole Magnesium)</title>
            <description>Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
esomeprazole magnesium: Given orally placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium)</title>
            <description>Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium)</title>
            <description>Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to the interventional agent, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The number of patients reporting adverse events will be tabulated by grade.</description>
          <population>All 120 patients that took study medication were evaluable for this secondary endpoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 or Higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 or Higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Placebo, Esomeprazole Magnesium)</title>
          <description>Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium)</title>
          <description>Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
        <group group_id="E3">
          <title>Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium)</title>
          <description>Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
acetylsalicylic acid: Given orally esomeprazole magnesium: Given orally placebo: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul J. Limburg, M.D., M.P.H.</name_or_title>
      <organization>Mayo Clinic Rochester</organization>
      <email>limburg.paul@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

